Abstract: Using a serum-free defined medium, a human cell line, NCI-H929, was established from a malignant effusion occuring in a patient with IgAk myeloma. The cultured cells have the morphologic, ultrastructural, biochemical, immunologic and cytochemical features of plasma cells. The cells have rearranged alpha and kappa genes and synthesize and secrete very high amounts of IgAk (>80 .mu.g/10.sup.6 cells/24 hr). The cells express surface immunoglobulin (alpha and kappa), the plasma cell antigen PCA-1, the transferrin receptor (T9) and T10, but lack antigens associated with earlier stages of B cell development (HLA-DR, B1, B2, B4, CALLA), as well as other leukocyte-macrophage antigens and Epstein-Barr virus nuclear antigen. While the tumor cells were predominantly near-diploid, the cultured cells are predominantly near-tetraploid with six copies of chromosome 8, four to six of which have an 8q+ abnormality.

Abstract: An accelerated method for making culturable cells which express bi-specific immunoglobulin employs a three cell fusion procedure which simultaneously fuses a myeloma cell with two B lymphocytes, each of which expresses antibody having a different antigenic specificity.

Abstract: A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.

Abstract: Disclosed herein is a method of enhancing the production of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (SCU-PA) by normal human lung diploid fibroblast cells in a serum-free medium. The method comprises the addition of heparin (or low molecular weight heparin) and an endothelial cell growth factor to the culture medium.

Abstract: The present invention is concerned with novel monoclonal antibodies specific for an antigenic site on a protein characteristic of a human basal cell and a malignant squamous cell. The antibodies do not bind to mesenchymal cells such as fibroblasts and endothelial cells. The protein on the cell surface which binds to one of the antibodies has a molecular weight of about 120,000 as determined by one dimensional gel electrophoresis. The antibodies find use in diagnostic methods such as the detection of malignant cells, e.g., the detection of residual tumor cells in skin subjected to microscopically-controlled surgery.

Abstract: Immortalized human bronchial epithelial and human mesothelial cell lines have been obtained. Various uses of these cell lines have been described.

Abstract: Monoclonal antibodies which demonstrate specific reactivity to cholesterol and methods for the detection of high levels of cholesterol by contacting biological specimens containing cholesterol with the monoclonal antibodies and measuring the formation of antigen-antibody complexes by immunosorbent assay.

Abstract: Hybridomally produced monoclonal IgM antibodies having high affinity are useful for the immunoassay and purification of viral antigens.

Abstract: Monoclonal antibody to toxin A of C.difficile has been prepared and is used in an assay for toxin A of C.difficile.

Abstract: A human physiologically active polypeptide, human Tumor Necrosis Factor (human TNF), comprising a specific amino acid sequence of 155 amino acid residues. The base sequence of the DNA coding for the human TNF has been determined using rabbit TNF cDNA. The human TNF can be advantageously produced on a large scale by recombinant DNA technique. The human TNF of the present invention has been found to be excellent in inducing necrosis of tumors with no toxic effect upon the normal tissues of the living body.

Abstract: A process for the detection of antibodies to HTLV III/LAV comprising:(A) mixing an unknown serum sample with a crude HTLV III/LAV viral antigen selected from the group consisting of(1) an antigen comprising P24 core protein and Penv protein;(2) a P24 antigen and(3) a Penv antigen,(B) incubating the resultant mixture from step (A);(C) contacting the mixture of step (B) with a solid substrate coated with antibody to HTLV III/LAV;(D) incubating the mass from step (C);(E) washing the mass from step (D);(F) contacting the mass from step (E) with a labeled antibody to HTLV III/LAV;(G) incubating the mass from step (F);(H) washing the mass from step (G);(I) assaying the label in the mass from step (H);(J) as a negative control, mixing a serum sample known to be negative to HTLV III/LAV antibody with a diluent;(K) subjecting the mass from step (J) to steps (B) to (I);(L) as a positive control, mixing a predetermined amount of the crude HTLV III/LAV viral antigen and the diluent;(M) subjecting the mass from step (L) t

Abstract: Attenuated pseudorabies viruses are provided which comprise DNA including a sequence essential for replication of the attenuated virus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring pseudorabies virus, from which at least a portion of a repeat sequence has been deleted. These viruses are useful as vaccines for immunizing animals against pseudorabies virus disease.The invention also provides methods of preparing attenuated pseudorabies viruses.

Abstract: Methods are described for assaying, in vitro, the capacity of a subject's lymphocytes to manifest suppressor function. PBLs are exposed to an agent stimulating suppressor cell formation and/or activation. Other PBLs are treated to induce a cell proliferative response, thereby producing responder cells. The responder cells are subjected to an antigen in the presence of the suppressor cells previously produced and in the presence of various concentrations of an amplifier. The procedure provides a means of ascertaining suppressor capacity of the subject's immune system, i.e., the subject's potential to express suppressor function, thereby permitting assay of severity of autoimmune disease, titrating dosage of immunomodulatory agents, and determining whether modulator therapy is feasible.

Abstract: The cold-adapted (ca) temperature-sensitive (ts) vaccine is prepared by serially passaging a suitably selected virus (e.g. Arkansas-type DPI strain) through a culture medium at a suboptimal replication temperature which is less than about 35.degree. C., e.g. 28.degree. C., and harvesting the live, cold-adapted mutant for formulation into dosage units of, for example, about 10.sup.3 to about 10.sup.5 EID.sub.50 /bird. The ca ts mutant is much less able to replicate at 40.degree.-42.degree. C. (internal avian body temperatures) than at the temperature of the bird's upper respiratory tract, which is below 40.degree. C. The vaccine can be administered by any of the usual techniques, including the spray technique. Vaccines of this invention appear to be very effective (immunogenic), but are also safe (non-pathogenic).

Abstract: Epithelial cells expressing foreign genetic material are described. The foreign genetic material can be DNA or RNA which does not occur in epithelial cells; DNA or RNA which occurs in epithelial cells but is not expressed in them at levels which are biologically significant; DNA or RNA which occurs in epithelial and has been modified so that it is expressed in epithelial cells; and any DNA or RNA which can be modified to be expressed in epithelial cells, alone or in any combination thereof. In addition, epithelial cells of the present invention can express genetic material encoding a selectable marker by which cells expressing the foreign genetic material can be expressed.

Abstract: Novel procoagulant proteins are disclosed which comprise the amino acid sequence:A-X-Bwherein region A represents the polypeptide sequence Ala-20 through Arg-759 substantially as shown in Table 1; region B represents the polypeptide sequence Ser-1709 through Tyr-2351 substantially as shown in Table 1; and region X represents a polypeptide sequence comprising up to 949 amino acids substantially duplicative of sequences of amino acids within the sequence SER-760 through Arg-1708 of Table 1, wherein the amino terminus of X is covalently bonded through a peptide bond designated "-" to the carboxy terminus of A, and the carboxy terminus of X is likewise bonded to the amino terminus of B. Methods of making such proteins and their use in pharmaceutical preparations is also disclosed.

Abstract: A hybrid cell line capable of producing monoclonal antibodies uniquely specific to human neutrophils and eosinophils and exhibiting no specificity for lymphocytes, basophils and monocytes. Further there is noreactivity with acute leukemia cells. One of the partners in the hybridoma fusion of a mouse spleen cell developed from using human granulocytes as the immunization agent. The monoclonal antibody further is capable of being used to enumerate and isolate neutrophils in normal peripheral blood and possibly in blood of patients with acute leukemia.

Abstract: A panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors as immunogen is used to diagnose the presence of lung tumors and differentiate between those which are benign and those which are cancerous.

Abstract: A method for determining the amino acid sequence of a polypeptide complementary to at least a portion of an original peptide or protein. In one aspect the method involves: (a) determining a first nucleotide sequence of a first nucleic acid coding for the biosynthesis of at least a portion of the original peptide or protein; (b) ascertaining a second nucleotide sequence of a second nucleic acid which base-pairs with the first nucleotide sequence of the first nucleic acid, the first and second nucleic acids pairing in antiparallel directions; and (c) determining the amino acid sequence of the complementary polypeptide by the second nucleotide sequence when read in the same reading frame as the first nucleotide sequence.

Abstract: DNA constructs consisting essentially of the promoter, gag, pol, and env sequences of a helper virus useful for making retrovirus packaging cell lines that do not yield helper virus and do not transfer the packaging function. Such DNA molecules are constructed by deleting from the genome of a replication-competent retrovirus all cis-acting elements except for the tRNA binding site. Specifically, deletion is made of the packaging signal, the site for initiation of second strand DNA synthesis, the site required for translation of reverse transcriptase during first strand DNA synthesis, and the provirus integration signal. DNA construct pPAM3 (ATCC No. 40234) is a representative embodiment. A cell line containing such an altered viral genome does not transmit this virus or transfer the packaging signal, but will transmit high titers of other viral RNAs containing the proper cis-acting elements, including retroviral vectors designed to carry foreign genes. Cell line PA317 (ATCC No.

Abstract: A quantitative assay for HAV comprises infecting at a temperature of from about 30.degree. to about 37.degree. C. a cell sheet with a dilution series of hepatitis A virus and then adding Newcastle disease virus (NDV) to the infected cell sheet and incubating the infected cell sheet in the presence of NDV at an elevated temperature for a time sufficient to permit a cytopathic effect (CPE) to become manifest, this time typically being at least about 4 days and preferably about 5 days. At an incubation temperature of from about 31.degree. to about 33.degree. C. the absence of CPE indicates the presence of HAV and the presence of CPE indicates the absence of HAV. At an incubation temperature of from about 34.degree. to about 36.degree. C. the absence of CPE indicates the absence of HAV and the presence of CPE indicates the presence of HAV.

Abstract: A new continuous rabbit cell line, designated TP-3, and variants thereof, which are hypoxyxanthineguanine-phosphoribosyl transferase deficient, hypoxyxanthine-aminopterine-thymidine sensitive, fast growing and non-antibody producing, and the methods for preparing the TP-3 cell line. Also, rabbit-rabbit hybrid cells formed by fusing the TP-3 cell line with antibody-producing cells from immunized rabbits, which hybrid cells are hypoxyxanthine-aminopterine-thymidine insensitve and secrete rabbit antibodies, and the methods for preparing the hybrid cells and hybrid cell lines. The invention further comprises rabbit monoclonal antibody.

Abstract: Monoclonal antibodies specifically immunologically reactive to thiol-modified glutathione and hybridoma cell lines producing such monoclonal antibodies. A method of producing antibodies specifically immunologically reactive with reduced glutathione by immunizing an animal using a thiol-modified glutathione, for example, a glutathione-N-ethylmaleimide-keyhole limpet hemocyanin conjugate. A method of utilizing the antibodies produced to quantitate the amount of reduced glutathione in a biological sample, to monitor glutathione-associated conditions, to monitor the formation of normal metabolic intermediates and to monitor the detoxification of foreign compounds.

Abstract: Double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.67 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 1 of the accompanying drawings; and double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.70 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 2 of the accompanying drawings; and hybrid DNAs having the double-stranded DNAs inserted thereinto.

Abstract: Method and compositions including monoclonal antibodies to a serogroup-common antigen are provided for the detection and diagnosis of Legionella pneumophila. The monoclonal antibodies recognize a proteinaceous antigen of molecular weight 28,000-29,000 Daltons which is detected in at least serogroups 1 through 8 of Legionella pneumophila and is not detected in other common respiratory pathogens.

Abstract: Nucleic acid hybridization probes for human papillomavirus types and particularly human papillomavirus type 44; and methods for employing the same.

Abstract: Nucleic acid hybridization probes for human papillomavirus types and particularly human papillomavirus type 35; and methods for employing the same.

Abstract: Nucleic acid hybridization probes for human papillomavirus types and particularly human papillomavirus type 43; and methods for employing the same.

Abstract: This invention provides monoclonal antibodies useful for the detection of Phythiaceae infection of plants. Hybridoma producing the antibodies as well as materials and kits for carrying out the detection of the organisms are also disclosed.

Abstract: A new method is described for fusing and selecting human-human hybrid cells. The selection process begins after longer incubation times in culture medium and involves selection without using HAT or any other drug regimen. Certain T-T cell hybrids produced in this manner secrete suppressor factor.

Abstract: This invention relates to a vaccine for canine heartworm. The invention further relates to a diagnostic test capable of discerning the presence of the canine heartworm parasite even in occult infections. The invention discloses kits and test strips suitable for diagnosing canine heartworm infections.

Abstract: Monoclonal antibodies reactive with epiglycanin.

Abstract: The invention provides a method for selecting hybridomas which produce antibodies specific to domains of a cell surface antigen which is usually not accessible at the surface of intact cells. The method employs the screening of the hybridoma clones obtained for the production of antibodies specific against the cell surface antigen by use of immunoblotting analysis, namely by screening the clones against antigen immobilized on a solid substrate such as nitrocellulose. The invention also includes those hybridomas and monoclonal antibodies when produced according to the method. The method provides monoclonal antibodies to P-glycoprotein surface antigen correlated with multidrug resistance. The antibodies are used to obtain a cDNA probe which in turn was used to select a cDNA clone encoding for a portion of the P-glycoprotein including the C-terminal end.

Abstract: Transformed human lymphocyte cell lines have been produced which secrete human monoclonal antibodies to serotypic determinants on LPS molecules of gram-negative bacteria. These antibodies have been found to be protective against lethal challenges of the homologous bacteria. Pharmaceutical compositions containing these antibodies and their prophylactic and therapeutic use in the management of gram-negative disease in humans are also disclosed.Human lymphocyte cell lines secreting human monoclonal antibodies specifically reacting with Pseudomonas aeruginosa Fisher immunotypes 1 (C5B7), 2 (6F11), 4 (C5D5), 5 (13C1), 6 (5G2) and 7 (8E7) were deposited at the American Type Culture Collection and given A.T.C.C. Accession Nos. CRL 8753, CRL 8562, CRL 8754, CRL 8796, CRL 8797 and CRL 8795, respectively.

Abstract: A method of effectively producing antobodies by creating antibody-producing hybrid cell lines utilizing an established B cell line as a parent cell lines and fusing these B cells to normal, human antibody-producing cells. A preferred established B cell line for use in this invention consists of B cells characterized by the presence of immunoglobulin at their cell surface.

Abstract: A composition suitable for topical application to mammalian skin or hair, comprises an amount of the cell-free supernatant from a culture of dermal papilla fibroblasts which is sufficient to increase hair growth in the rat, when applied thereto, by at least 10% more than that obtainable using a control composition from which the said cell-free supernatant has been omitted.

Abstract: For preventing or controlling bacterial harm to plants, as by disease or ice nucleation, a bateriophage composition of matter containing one or more viral h mutants specific to amutant of the bacteria concerned is produced and applied to seed, soil or soil supplements, plants, or plant materials that have been exposed to or are contaiminated with or infected by bacerial disease, or to growing plants subject to ice nucleation or other bacterial harm. The invention is concerned with the composition and with the method of producing and using same.

Abstract: Methods of determining the ratio of apolipoprotein B-100 to apolipoprotein A-I using ELISA techniques in conjunction with monoclonal paratopic molecules are disclosed as are diagnostic systems useful in performing those determinations. Monoclonal paratopic molecules secreted by hybridomas having ATCC accession numbers HB 8742, HB 8746, HB 9200 and HB 9201 are utilized.

Abstract: Competitive immunoassays, which employ idiotypic and antiidiotypic monoclonal antibody reagents, are described. These competitive immunoassays are particularly useful for the detection of low concentrations of analyte for which labeled reference analyte is difficult to obtain in quantity. Antiidiotypic monoclonal antibody reagents serves as a substitute for the labeled reference analyte. The antiidiotypic monoclonal antibody reagent exhibits a congruency of structure with one or more epitopes of the analyte or antigen. The antiidiotypic monoclonal antibody is prepared against an idiotypic monoclonal antibody, which, in turn, was prepared against the antigen or analyte. During the immunoassay, the antiidiotypic monoclonal antibody is allowed to compete with the antigen, whose concentration is being determined, for a limited number of antibody binding sites present on an idiotypic antibody, which was also prepared against the antigen or analyte.

Abstract: The present invention discloses a biologically active basement membrane composition. When polymerized under physiological conditions, the composition forms gel-like structures whose ultrastructure resembles interconnected thin sheets of the lamina densa zone of basement membrane. The major components of the composition include laminin, type IV collagen, heparin sulfate proteoglycan, entactin and nidogen. These components polymerize in constant proportions when redissolved and allowed to reconstitute. Molecular sieve studies on the soluble extract demonstrate that laminin, entactin and nidogen are associated in a large but dissociable complex. The reconstituted matrix is biologically active and stimulates the growth and differentiation of a variety of cells, including epithelial cells, nerve cells, hair follicles and the like. The reconstituted matrix can also be used for determining metastatic potential of tumor cells and for isolating metastatic tumor cells.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 70% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: A mutant T-cell line of HSB-2-ERICR which produces a T cell Growth Factor is disclosed. The Mutant cells are sensitive to HAT Medium.

Abstract: A diagnostic site-specific imaging reagent in the form of a receptor and an indicating means selectively binds to a specific cell membrane-associated antigen of a blood platelet that is in a stimulated active state but does not substantially bind to a platelet that is in a non-stimulated resting state. In particular, prelabelled monoclonal antibodies and polyclonal antibodies are prepared that bind and image thrombospondin when it is cell membrane-associated on a thrombin-stimulated platelet, thereby providing means for detecting and discriminating between a stimulated active blood platelet and a non-stimulated resting blood platelet.

Abstract: A competitive immunoassay for a steroid receptor has been developed in which monoclonal antibodies capable of binding to the steroid receptor are competitively bound by anti-steroid antibodies capable of binding to the steroid. The presence or amount of monoclonal antibody-anti-steroid antibody complex formed is related to the amount of steroid receptor present in the assayed material.A histochemical assay is also provided for detecting the amount of a steroid-receptor complex in a biological sample. This assay involves (1) adding an amount of steroid to the sample to form a steroid-receptor complex; (2) contacting the complex with a monoclonal antibody capable of binding to the complex; (3) removing any unbound monoclonal antibody; (4) adding a detectably labeled antibody capable of binding to the monoclonal antibody; (5) determining the amount of labeled antibody bound to the monoclonal antibody; and (6) determining the amount of steroid-receptor complex.

Abstract: A single-antibody inhibition assay for detecting antibody to HBcAg using a labeled monoclonal antibody. A competitive ELISA method of screening hybridoma supernatants for monoclonal antibodies to HBcAg. A method of producing high affinity monoclonal antibody to rHBcAg by immunizing a mouse with rHRcAg using a short immunization schedule. Monoclonal antibodies to immunodominant epitope of HBcAg.

Abstract: PrU.S. GOVERNMENT RIGHTSThe invention described herein was made in the course of work under a grant or award from the National Institutes of Health. The U.S. Government has certain rights in this invention pursuant to such grant or award.

Abstract: A method of testing a fluid sample for the presence of antibodies against a micro-organism, which comprises contacting the sample with fixed cells or fragments of cells infected with the micro-organism, and determining the presence of antibody bound to the cell-associated antigens, in which the determination is by virtue of a color change visible to the naked-eye at the site of the antibodies. For use in a testing method of this type, a test component comprises upper and lower layers, in which the upper layer has an array of apertures through which discrete areas on the lower layer are exposed, and in which the lower layer carries, in some at least of the discrete areas, fixed cells or cell fragments infected by a micro-organism.

Abstract: The present invention provides an interleukin-2 composition which comprises human serum albumin, a reducing compound or a combination thereof and is adjusted as showing pH of 3 to 6 as a solution. The composition of the present invention is characterized in that interleukin-2 activity is minimized during storage and in the processes of freezing and lyophilization.

Abstract: Substantially genetically stable continuous human cell lines derived from normal human mammary epithelial cells (HMEC) and processes for making and using the same. In a preferred embodiment, the cell lines are derived by treating normal human mammary epithelial tissue with a chemical carcinogen such as benzo[a]pyrene. The novel cell lines serve as useful substrates for elucidating the potential effects of a number of toxins, carcinogens and mutagens as well as of the addition of exogenous genetic material. The autogenic parent cells from which the cell lines are derived serve as convenient control samples for testing. The cell lines are not neoplastically transformed, although they have acquired several properties which distinguish them from their normal progenitors.

Abstract: Cell fusion is induced between tumor cells that do not secrete a desired protein and mammalian cells or microcells derived from mammalian cells which secrete the desired protein, by substantially removing at least calcium ions to destabilize the cell membranes, adding a fusogen to the destabilized cells, and then adding back polyvalent cations.